JPMorgan Doesn't Rule Out Amarin (AMRN) Exploring Sale/Partnership into ANCHOR sNDA, NCE

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to JPMorgan Doesn't Rule Out Amarin (AMRN) Exploring Sale/Partnership into ANCHOR sNDA, NCE

Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa

December 14, 2012 1:07 PM EST

Amarin (Nasdaq: AMRN) shares are higher on the session as traders anticipate an NCE decision on Vascepa sometime today, though nothing is in stone.

Shares are 24 percent lower from the close on December 6th, with Amarin... More

Amarin (AMRN) Down 16% after No Sale

December 6, 2012 4:06 PM EST

Amarin Corp Plc (NASDAQ: AMRN) is down a quick 16%, but off the lows, after announcing a $100 million non-equity financing and hiring Vascepa sales force. Investors are disappointed that there was no sale.... More

Amarin (AMRN) Enters $100M Non-Equity Financing Agreement; Hiring for Vascepa Sales Launch

December 6, 2012 4:03 PM EST

Amarin Corporation plc (Nasdaq: AMRN) announced today a $100 million non-equity financing with an investment fund managed by Pharmakon Advisors and that Amarin is continuing its preparations to commercialize Vascepa® (icosapent ethyl) capsules with the hiring of a sales force in the United States. Payments by Amarin under this hybrid debt-like instrument are expected to be made over a 3.5-year period commencing in November 2013 and to continue through early 2017.

As... More